nach oben

Diabetologia

Erschienen in:

01.06.2014 | Review

Myokines in insulin resistance and type 2 diabetes

verfasst von: Kristin Eckardt, Sven W. Görgens, Silja Raschke, Jürgen Eckel

Erschienen in: Diabetologia | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Skeletal muscle represents the largest organ of the body in non-obese individuals and is now considered to be an active endocrine organ releasing a host of so-called myokines. These myokines are part of a complex network that mediates communication between muscle, the liver, adipose tissue, the brain and other organs. Recent data suggest that myokines regulated by muscle contraction may play a key role in mediating the health-promoting effects of regular physical activity. Although hundreds of myokines have recently been described in proteomic studies, we currently have a rather limited knowledge of the specific role these myokines play in the prevention of insulin resistance, inflammation and associated metabolic dysfunction. Several myokines are known to have both local and endocrine functions, but in many cases the contribution of physical activity to the systemic level of these molecules remains as yet unexplored. Very recently, novel myokines such as irisin, which is thought to induce a white to brown shift in adipocytes, have gained considerable interest as potential therapeutic targets. In this review, we summarise the most recent findings on the role of myokines in the regulation of substrate metabolism and insulin sensitivity. We further explore the role of myokines in the regulation of inflammation and provide a critical assessment of irisin and other myokines regarding their potential as therapeutic targets.

Febbraio MA, Pedersen BK (2005) Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exerc Sport Sci Rev 33:114–119PubMed

Raschke S, Eckardt K, Holven KB, Jensen J, Eckel J (2013) Identification and validation of novel contraction-regulated myokines released from primary human skeletal muscle cells. PLoS One 8:e62008PubMedCentralPubMed

Hartwig S, Raschke S, Knebel B et al (2013) Secretome profiling of primary human skeletal muscle cells. Biochim Biophys Acta. doi:10.1016/j.bbr.2011.03.031 PubMed

Norheim F, Raastad T, Thiede B, Rustan AC, Drevon CA, Haugen F (2011) Proteomic identification of secreted proteins from human skeletal muscle cells and expression in response to strength training. Am J Physiol Endocrinol Metab 301:E1013–E1021PubMed

Raschke S, Eckel J (2013) Adipo-myokines: two sides of the same coin—mediators of inflammation and mediators of exercise. Mediat Inflamm 2013:320724

Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8:457–465PubMed

Thyfault JP, Booth FW (2011) Lack of regular physical exercise or too much inactivity. Curr Opin Clin Nutr Metab Care 14:374–378PubMed

Bergouignan A, Rudwill F, Simon C, Blanc S (2011) Physical inactivity as the culprit of metabolic inflexibility: evidences from bed-rest studies. J Appl Physiol 11:1201–1210

Alibegovic AC, Sonne MP, Hojbjerre L et al (2010) Insulin resistance induced by physical inactivity is associated with multiple transcriptional changes in skeletal muscle in young men. Am J Physiol Endocrinol Metab 299:E752–E763PubMed

10.

Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund PB (2000) Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529:237–242PubMedCentralPubMed

11.

Steensberg A, Febbraio MA, Osada T et al (2001) Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol 537:633–639PubMedCentralPubMed

12.

Hiscock N, Chan MH, Bisucci T, Darby IA, Febbraio MA (2004) Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J 18:992–994PubMed

13.

Pedersen BK, Febbraio MA (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88:1379–1406PubMed

14.

Whitham M, Chan MH, Pal M et al (2012) Contraction-induced interleukin-6 gene transcription in skeletal muscle is regulated by c-Jun terminal kinase/activator protein-1. J Biol Chem 287:10771–10779PubMedCentralPubMed

15.

Nieto-Vazquez I, Fernandez-Veledo S, de Alvaro C, Lorenzo M (2008) Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 57:3211–3221PubMedCentralPubMed

16.

Holmes AG, Mesa JL, Neill BA et al (2008) Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARα and UCP2 expression in rats. J Endocrinol 198:367–374PubMed

17.

Sadagurski M, Norquay L, Farhang J, D’Aquino K, Copps K, White MF (2010) Human IL6 enhances leptin action in mice. Diabetologia 53:525–535PubMedCentralPubMed

18.

Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A (2006) Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 20:3364–3375PubMed

19.

Carey AL, Steinberg GR, Macaulay SL et al (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55:2688–2697PubMed

20.

Jiang LQ, Duque-Guimaraes DE, Machado UF, Zierath JR, Krook A (2012) Altered response of skeletal muscle to IL-6 in type 2 diabetic patients. Diabetes 62:355–361PubMed

21.

Febbraio MA, Steensberg A, Keller C et al (2003) Glucose ingestion attenuates interleukin-6 release from contracting skeletal muscle in humans. J Physiol 549:607–612PubMedCentralPubMed

22.

Keller C, Steensberg A, Pilegaard H et al (2001) Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 15:2748–2750PubMed

23.

Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK (2004) Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53:1643–1648PubMed

24.

Steensberg A, Fischer CP, Sacchetti M et al (2003) Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548:631–638PubMedCentralPubMed

25.

Fritsche L, Hoene M, Lehmann R et al (2010) IL-6 deficiency in mice neither impairs induction of metabolic genes in the liver nor affects blood glucose levels during fasting and moderately intense exercise. Diabetologia 53:1732–1742PubMed

26.

Kim HJ, Higashimori T, Park SY et al (2004) Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060–1067PubMed

27.

Klover PJ, Zimmers TA, Koniaris LG, Mooney RA (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784–2789PubMed

28.

Jiang LQ, Franck N, Egan B et al (2013) Autocrine role of interleukin-13 on skeletal muscle glucose metabolism in type 2 diabetic patients involves microRNA let-7. Am J Physiol Endocrinol Metab 305:E1359–E1366PubMed

29.

Stanya KJ, Jacobi D, Liu S et al (2013) Direct control of hepatic glucose production by interleukin-13 in mice. J Clin Invest 123:261–271PubMedCentralPubMed

30.

van Hall G, Steensberg A, Sacchetti M et al (2003) Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005–3010PubMed

31.

Wolsk E, Mygind H, Grondahl TS, Pedersen BK, van Hall G (2010) IL-6 selectively stimulates fat metabolism in human skeletal muscle. Am J Physiol Endocrinol Metab 299:E832–E840PubMed

32.

Petersen EW, Carey AL, Sacchetti M et al (2005) Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288:E155–E162PubMed

33.

Kelly M, Gauthier MS, Saha AK, Ruderman NB (2009) Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes 58:1953–1960PubMedCentralPubMed

34.

Macdonald TL, Wan Z, Frendo-Cumbo S, Dyck DJ, Wright DC (2013) IL-6 and epinephrine have divergent fiber type effects on intramuscular lipolysis. J Appl Physiol (1985) 115:1457–1463

35.

Peterson JM, Pizza FX (2009) Cytokines derived from cultured skeletal muscle cells after mechanical strain promote neutrophil chemotaxis in vitro. J Appl Physiol 106:130–137PubMed

36.

Nieman DC, Davis JM, Brown VA et al (2004) Influence of carbohydrate ingestion on immune changes after 2 h of intensive resistance training. J Appl Physiol 96:1292–1298PubMed

37.

Nielsen AR, Mounier R, Plomgaard P et al (2007) Expression of interleukin-15 in human skeletal muscle effect of exercise and muscle fibre type composition. J Physiol 584:305–312PubMedCentralPubMed

38.

Tamura Y, Watanabe K, Kantani T, Hayashi J, Ishida N, Kaneki M (2011) Upregulation of circulating IL-15 by treadmill running in healthy individuals: is IL-15 an endocrine mediator of the beneficial effects of endurance exercise? Endocr J 58:211–215PubMed

39.

Yeo NH, Woo J, Shin KO, Park JY, Kang S (2012) The effects of different exercise intensity on myokine and angiogenesis factors. J Sports Med Phys Fitness 52:448–454PubMed

40.

Riechman SE, Balasekaran G, Roth SM, Ferrell RE (2004) Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses. J Appl Physiol 97:2214–2219

41.

Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, Al-Abri S, Al-Lawati J, Al-Maskari M (2013) Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol 2013:976810PubMedCentralPubMed

42.

Barra NG, Reid S, MacKenzie R et al (2010) Interleukin-15 contributes to the regulation of murine adipose tissue and human adipocytes. Obesity (Silver Spring) 18:1601–1607

43.

Almendro V, Busquets S, Ametller E et al (2006) Effects of interleukin-15 on lipid oxidation: disposal of an oral [¹⁴C]-triolein load. Biochim Biophys Acta 1761:37–42PubMed

44.

Quinn LS, Strait-Bodey L, Anderson BG, Argiles JM, Havel PJ (2005) Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signaling pathway. Cell Biol Int 29:449–457PubMed

45.

Quinn LS, Anderson BG, Strait-Bodey L, Stroud AM, Argiles JM (2009) Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol Metab 296:E191–E202PubMedCentralPubMed

46.

Matthews VB, Astrom MB, Chan MH et al (2009) Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia 52:1409–1418PubMed

47.

Krabbe KS, Nielsen AR, Krogh-Madsen R et al (2007) Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50:431–438PubMed

48.

Rasmussen P, Brassard P, Adser H et al (2009) Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp Physiol 94:1062–1069PubMed

49.

Tsuchida A, Nakagawa T, Itakura Y et al (2001) The effects of brain-derived neurotrophic factor on insulin signal transduction in the liver of diabetic mice. Diabetologia 44:555–566PubMed

50.

Bouzakri K, Plomgaard P, Berney T, Donath MY, Pedersen BK, Halban PA (2011) Bimodal effect on pancreatic beta-cells of secretory products from normal or insulin-resistant human skeletal muscle. Diabetes 60:1111–1121PubMedCentralPubMed

51.

Ellingsgaard H, Ehses JA, Hammar EB et al (2008) Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 105:13163–13168PubMedCentralPubMed

52.

Ellingsgaard H, Hauselmann I, Schuler B et al (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17:1481–1489PubMed

53.

Ueda SY, Yoshikawa T, Katsura Y, Usui T, Nakao H, Fujimoto S (2009) Changes in gut hormone levels and negative energy balance during aerobic exercise in obese young males. J Endocrinol 201:151–159PubMed

54.

Martins C, Robertson MD, Morgan LM (2008) Effects of exercise and restrained eating behaviour on appetite control. Proc Nutr Soc 67:28–41PubMed

55.

Shirazi R, Palsdottir V, Collander J et al (2013) Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc Natl Acad Sci U S A 110:16199–16204PubMedCentralPubMed

56.

Henningsen J, Rigbolt KT, Blagoev B, Pedersen BK, Kratchmarova I (2010) Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol Cell Proteomics 9:2482–2496PubMedCentralPubMed

57.

Shah R, Hinkle CC, Ferguson JF et al (2011) Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 60:1512–1518PubMedCentralPubMed

58.

Plomgaard P, Hansen J, Bianda V, Pedersen BK, Bouzakri K (2013) Fractalkine is a novel myokine which protects myotubes from TNF-alpha induced insulin resistance. Diabetologia 56(Suppl 1):S79 (Abstract 178)

59.

Lee YS, Morinaga H, Kim JJ et al (2013) The fractalkine/CX3CR1 system regulates beta cell function and insulin secretion. Cell 153:413–425PubMedCentralPubMed

60.

Sell H, Habich C, Eckel J (2012) Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 8:709–716PubMed

61.

Gleeson M (2007) Immune function in sport and exercise. J Appl Physiol 103:693–699PubMed

62.

Pedersen BK, Saltin B (2006) Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports 16(Suppl 1):3–63PubMed

63.

Donges CE, Duffield R, Drinkwater EJ (2010) Effects of resistance or aerobic exercise training on interleukin-6, C-reactive protein, and body composition. Med Sci Sports Exerc 42:304–313PubMed

64.

Christiansen T, Paulsen SK, Bruun JM, Pedersen SB, Richelsen B (2010) Exercise training versus diet-induced weight-loss on metabolic risk factors and inflammatory markers in obese subjects: a 12-week randomized intervention study. Am J Physiol Endocrinol Metab 298:E824–E831PubMed

65.

Fischer CP, Berntsen A, Perstrup LB, Eskildsen P, Pedersen BK (2007) Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. Scand J Med Sci Sports 17:580–587PubMed

66.

Drummond MJ, Timmerman KL, Markofski MM et al (2013) Short-term bed rest increases TLR4 and IL-6 expression in skeletal muscle of older adults. Am J Physiol Regul Integr Comp Physiol 305:R216–R223PubMed

67.

King DE, Carek P, Mainous AG III, Pearson WS (2003) Inflammatory markers and exercise: differences related to exercise type. Med Sci Sports Exerc 35:575–581PubMed

68.

Abramson JL, Vaccarino V (2002) Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med 162:1286–1292PubMed

69.

Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP (2001) Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 153:242–250PubMed

70.

Mattusch F, Dufaux B, Heine O, Mertens I, Rost R (2000) Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med 21:21–24PubMed

71.

de Lemos ET, Oliveira J, Pinheiro JP, Reis F (2012) Regular physical exercise as a strategy to improve antioxidant and anti-inflammatory status: benefits in type 2 diabetes mellitus. Oxidative Med Cell Longev 2012:741545

72.

Stewart LK, Flynn MG, Campbell WW et al (2007) The influence of exercise training on inflammatory cytokines and C-reactive protein. Med Sci Sports Exerc 39:1714–1719PubMed

73.

Francaux M (2009) Toll-like receptor signalling induced by endurance exercise. Appl Physiol Nutr Metab 34:454–458PubMed

74.

Lambert CP, Wright NR, Finck BN, Villareal DT (2008) Exercise but not diet-induced weight loss decreases skeletal muscle inflammatory gene expression in frail obese elderly persons. J Appl Physiol (1985) 105:473–478

75.

Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA (2011) The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 11:607–615PubMed

76.

Liang H, Hussey SE, Sanchez-Avila A, Tantiwong P, Musi N (2013) Effect of lipopolysaccharide on inflammation and insulin action in human muscle. PLoS One 8:e63983PubMedCentralPubMed

77.

Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-α production in humans. FASEB J 17:884–886PubMed

78.

Lambernd S, Taube A, Schober A et al (2012) Contractile activity of human skeletal muscle cells prevents insulin resistance by inhibiting pro-inflammatory signalling pathways. Diabetologia 55:1128–1139PubMed

79.

Pedersen BK, Akerstrom TC, Nielsen AR, Fischer CP (2007) Role of myokines in exercise and metabolism. J Appl Physiol 103:1093–1098PubMed

80.

Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4–7PubMed

81.

Duncan BB, Schmidt MI, Pankow JS et al (2003) Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52:1799–1805PubMed

82.

Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751PubMed

83.

Im SH, Rao A (2004) Activation and deactivation of gene expression by Ca²⁺/calcineurin-NFAT-mediated signaling. Mol Cells 18:1–9PubMed

84.

Banzet S, Koulmann N, Sanchez H et al (2007) Contraction-induced interleukin-6 transcription in rat slow-type muscle is partly dependent on calcineurin activation. J Cell Physiol 210:596–601PubMed

85.

Chan MH, McGee SL, Watt MJ, Hargreaves M, Febbraio MA (2004) Altering dietary nutrient intake that reduces glycogen content leads to phosphorylation of nuclear p38 MAP kinase in human skeletal muscle: association with IL-6 gene transcription during contraction. FASEB J 18:1785–1787PubMed

86.

Petersen AM, Pedersen BK (2005) The anti-inflammatory effect of exercise. J Appl Physiol 98:1154–1162PubMed

87.

Dinarello CA (2000) The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 343:732–734PubMed

88.

Görgens SW, Eckardt K, Elsen M, Tennagels N, Eckel J (2014) Chitinase-3-like protein 1 protects skeletal muscle from TNFα-induced inflammation and insulin resistance. Biochem J. doi:10.1042/BJ20131151 PubMed

89.

Nielsen AR, Erikstrup C, Johansen JS et al (2008) Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 57:3078–3082PubMedCentralPubMed

90.

Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK (1999) Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol 515:287–291PubMedCentralPubMed

91.

Bernecker C, Scherr J, Schinner S, Braun S, Scherbaum WA, Halle M (2013) Evidence for an exercise induced increase of TNF-α and IL-6 in marathon runners. Scand J Med Sci Sports 23:207–214PubMed

92.

Paulsen G, Mikkelsen UR, Raastad T, Peake JM (2012) Leucocytes, cytokines and satellite cells: what role do they play in muscle damage and regeneration following eccentric exercise? Exerc Immunol Rev 18:42–97PubMed

93.

Sigal RJ, Kenny GP, Boule NG et al (2007) Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 147:357–369PubMed

94.

Cypess AM, Lehman S, Williams G et al (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360:1509–1517PubMedCentralPubMed

95.

Ouellet V, Routhier-Labadie A, Bellemare W et al (2011) Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of ¹⁸F-FDG-detected BAT in humans. J Clin Endocrinol Metab 96:192–199PubMed

96.

Zingaretti MC, Crosta F, Vitali A et al (2009) The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. FASEB J 23:3113–3120PubMed

97.

van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM et al (2009) Cold-activated brown adipose tissue in healthy men. N Engl J Med 360:1500–1508PubMed

98.

Bostrom P, Wu J, Jedrychowski MP et al (2012) A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463–468PubMedCentralPubMed

99.

Camporez JP, Jornayvaz FR, Petersen MC et al (2013) Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 154:3099–3109PubMed

100.

Raschke S, Elsen M, Gassenhuber H et al (2013) Evidence against a beneficial effect of irisin in humans. PLoS One 8:e73680PubMedCentralPubMed

101.

Erickson HP (2013) Irisin and FNDC5 in retrospect: an exercise hormone or a transmembrane receptor? Adipocyte 2:289–293PubMedCentralPubMed

102.

Timmons JA, Baar K, Davidsen PK, Atherton PJ (2012) Is irisin a human exercise gene? Nature 488:E9–E10PubMed

103.

Pekkala S, Wiklund P, Hulmi JJ et al (2013) Are skeletal muscle FNDC5 gene expression and irisin release regulated by exercise and related to health? J Physiol 591:5393–5400PubMed

104.

Norheim F, Langleite TM, Hjorth M et al (2014) The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. FEBS J 281:739–749PubMed

105.

Huh JY, Panagiotou G, Mougios V et al (2012) FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61:1725–1738PubMedCentralPubMed

106.

Kraemer RR, Shockett P, Webb ND, Shah U, Castracane VD (2014) A transient elevated irisin blood concentration in response to prolonged, moderate aerobic exercise in young men and women. Horm Metab Res 46:150–154PubMed

107.

Gouni-Berthold I, Berthold HK, Huh JY et al (2013) Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS ONE 8:e72858PubMedCentralPubMed

108.

Moreno-Navarrete JM, Ortega F, Serrano M et al (2013) Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 98:E769–E778PubMed

109.

Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF (2013) Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity—correlation with body mass index. Peptides 39:125–130PubMed

110.

Choi YK, Kim MK, Bae KH et al (2013) Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 100:96–101PubMed

111.

Zhang Y, Li R, Meng Y et al (2013) Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 63:514–525PubMed

112.

Lee D, Zhou Y, Tu M et al (2013) Irisin does not induce browning of mouse or human adipocytes. Diabetes 62(Suppl 1):A25 (Abstract)

113.

Cheng X, Zhu B, Jiang F, Fan H (2011) Serum FGF-21 levels in type 2 diabetic patients. Endocr Res 36:142–148PubMed

114.

Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K (2008) FGF21 is an Akt-regulated myokine. FEBS Lett 582:3805–3810PubMedCentralPubMed

115.

Hojman P, Pedersen M, Nielsen AR et al (2009) Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 58:2797–2801PubMedCentralPubMed

116.

Yang SJ, Hong HC, Choi HY et al (2011) Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf) 75:464–469

117.

Besse-Patin A, Montastier E, Vinel C et al (2013) Effect of endurance training on skeletal muscle myokine expression in obese men: identification of apelin as a novel myokine. Int J Obes (Lond). doi:10.1038/ijo.2013.158

118.

Cuevas-Ramos D, Almeda-Valdes P, Meza-Arana CE et al (2012) Exercise increases serum fibroblast growth factor 21 (FGF21) levels. PLoS One 7:e38022PubMedCentralPubMed

119.

Kim KH, Kim SH, Min YK, Yang HM, Lee JB, Lee MS (2013) Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS One 8:e63517PubMedCentralPubMed

120.

Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426–437PubMed

121.

Inagaki T, Dutchak P, Zhao G et al (2007) Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 5:415–425PubMed

122.

Cuevas-Ramos D, Aguilar-Salinas CA, Gomez-Perez FJ (2012) Metabolic actions of fibroblast growth factor 21. Curr Opin Pediatr 24:523–529PubMed

123.

Coskun T, Bina HA, Schneider MA et al (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018–6027PubMed

124.

Kharitonenkov A, Shiyanova TL, Koester A et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627–1635PubMedCentralPubMed

125.

Kharitonenkov A, Wroblewski VJ, Koester A et al (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774–781PubMed

126.

Xu J, Lloyd DJ, Hale C et al (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250–259PubMedCentralPubMed

127.

Holland WL, Adams AC, Brozinick JT et al (2013) An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 17:790–797PubMedCentralPubMed

128.

Lin Z, Tian H, Lam KS et al (2013) Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 17:779–789PubMed

129.

Gaich G, Chien JY, Fu H et al (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18:333–340PubMed

130.

Ouchi N, Oshima Y, Ohashi K et al (2008) Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem 283:32802–32811PubMedCentralPubMed

131.

Gorgens SW, Raschke S, Holven KB, Jensen J, Eckardt K, Eckel J (2013) Regulation of follistatin-like protein 1 expression and secretion in primary human skeletal muscle cells. Arch Physiol Biochem 119:75–80PubMed

132.

Lehr S, Hartwig S, Lamers D et al (2012) Identification and validation of novel adipokines released from primary human adipocytes. Mol Cell Proteomics 11:M111.010504PubMedCentralPubMed

133.

Shimano M, Ouchi N, Nakamura K et al (2011) Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. Proc Natl Acad Sci U S A 108:E899–E906PubMedCentralPubMed

134.

Oshima Y, Ouchi N, Sato K, Izumiya Y, Pimentel DR, Walsh K (2008) Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation 117:3099–3108PubMedCentralPubMed

135.

Ogura Y, Ouchi N, Ohashi K et al (2012) Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation 126:1728–1738PubMedCentralPubMed

136.

Mashili FL, Austin RL, Deshmukh AS et al (2011) Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev 27:286–297PubMed

137.

Potthoff MJ, Inagaki T, Satapati S et al (2009) FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A 106:10853–10858PubMedCentralPubMed

138.

Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492:203–206PubMed

139.

Adams DC, Karolak MJ, Larman BW, Liaw L, Nolin JD, Oxburgh L (2010) Follistatin-like 1 regulates renal IL-1β expression in cisplatin nephrotoxicity. Am J Physiol Ren Physiol 299:F1320–F1327

Titel: Myokines in insulin resistance and type 2 diabetes
verfasst von: Kristin Eckardt
Sven W. Görgens
Silja Raschke
Jürgen Eckel
Publikationsdatum: 01.06.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 6/2014
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-014-3224-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Myokines in insulin resistance and type 2 diabetes

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2014

Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT)

Erratum to: Modulation of p75NTR prevents diabetes- and proNGF-induced retinal inflammation and blood–retina barrier breakdown in mice and rats

Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic

A serum 25-hydroxyvitamin D concentration-associated genetic variant in DHCR7 interacts with type 2 diabetes status to influence subclinical atherosclerosis (measured by carotid intima–media thickness)

Muscle-specific activation of Ca2+/calmodulin-dependent protein kinase IV increases whole-body insulin action in mice

Elevated resistin levels induce central leptin resistance and increased atherosclerotic progression in mice

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin